The purpose of this observational study is to collect long-term data on safety and effectiveness of fingolimod, particularly including clinical disease and patient outcome related parameters such as relapse and disability, in patients who have participated in prior trials within the fingolimod clinical development program. Furthermore, this study explores the incidence of selected safety related outcomes of fingolimod treatment during follow-up visits within the context of routine medical practice.
Study Type
OBSERVATIONAL
Enrollment
64
Long-term safety data in patients with relapsing forms of multiple sclerosis who have participated in clinical trials with fingolimod and who are now taking prescribed fingolimod under the conditions of routine medical practice
Time frame: Throughout the entirety of the study up to a maximum of 8 years
Long-term effectiveness data, particularly including clinical disease and patient outcome related parameters such as relapse and disability
Time frame: Throughout the entirety of the study up to a maximum of 8 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
North Central Neurology Associates, PC
Cullman, Alabama, United States
The Research & Education Inst. of Alta Bates Summit Med. Grp
Berkeley, California, United States
Neuro-Therapeutics, Inc.
Pasadena, California, United States
University of California San Francisco
San Francisco, California, United States
Yale Multiple Sclerosis Center
New Haven, Connecticut, United States
Georgetown University/Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Sunrise Clinical Research, Inc.
Hollywood, Florida, United States
University of Florida
Jacksonville, Florida, United States
University of Miami
Miami, Florida, United States
Neurological Associates
Pompano Beach, Florida, United States
...and 48 more locations